SP
Sejal Prakash Sheladia
About Sejal Prakash Sheladia
Data last updated:
Sejal Prakash Sheladia is a Director at Archon Healthcare Private Limited (since 2017) and Director at Cureevo Medglobal Private Limited (since 2025). The companies operate in Pharma. The largest current company by reported revenue is Archon Healthcare Private Limited at ₹1.80 Cr (FY 2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 11 Apr 2017 | 2013 | ₹1.80 Cr (FY 2022) | Active | |
| Director | 03 Dec 2025 | 2025 | Active |
Board colleagues of Sejal Prakash Sheladia
| Name | DIN | Company | Designation |
|---|---|---|---|
| Prakash Gokalbhai Sheladia | 06602484 | Archon Healthcare Private Limited | Director |
| Manishabahen Urmil Panchal | 11407079 | Cureevo Medglobal Private Limited | Director |
| Minaben Jitendrakumar Prajapati | 11407078 | Cureevo Medglobal Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sejal Prakash Sheladia
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sejal Prakash Sheladia
Sejal Prakash Sheladia currently holds 2 directorships: Archon Healthcare Private Limited (Director, since 11 Apr 2017, revenue ₹1.80 Cr (FY 2022)); Cureevo Medglobal Private Limited (Director, since 03 Dec 2025).
Sejal Prakash Sheladia was first appointed on 11 Apr 2017 as Director at Archon Healthcare Private Limited. The most recent appointment on record is 03 Dec 2025 at Cureevo Medglobal Private Limited.
The current boards of Sejal Prakash Sheladia's companies include Prakash Gokalbhai Sheladia (Archon Healthcare Private Limited), Manishabahen Urmil Panchal (Cureevo Medglobal Private Limited), Minaben Jitendrakumar Prajapati (Cureevo Medglobal Private Limited).